Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-01-11

Clinical Trial Update: A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two doses of CP-690,550 (tofacitinib) against placebo in rheumatoid arthritis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CP-690,550 (tofacitinib)
  • Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2013-01-11